Last quarter (Q3 2023), MoonLake Immunotherapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, MoonLake Immunotherapeutics's net income was $-9.43M. See MoonLake Immunotherapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20
Total Revenue	$ -2.30M	-	$ 2.30M	$ 0.00
Cost of Revenue	-	-	-	-
Gross Profit	$ -2.30M	-	$ 2.30M	-
Operating Expense	$ 3.74M	$ -65.06M	$ 4.57M	$ 105.75K
Operating Income	$ -69.02M	$ -65.06M	$ -4.57M	$ -105.75K
Net Non Operating Interest Income Expense	$ -7.77K	-	$ 27.69K	$ 14.92K
Other Income Expense	$ 11.74M	$ -591.73K	$ -9.10M	-
Pretax Income	$ -65.77M	$ -64.47M	$ -4.54M	$ -90.84K
Tax Provision	$ 68.43K	$ 36.37K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-
Net Income Common Stockholders	$ -53.61M	$ -49.97M	$ -4.54M	$ -90.84K
Basic EPS	$ -1.73	$ -1.70	-	$ -0.03
Diluted EPS	$ -1.37	$ -1.70	$ -0.31	$ -0.03
Basic Average Shares	$ 165.66M	$ 29.36M	$ 11.93M	$ 2.70M
Diluted Average Shares	$ 165.66M	$ 29.36M	$ 360.00M	$ 8.93M
Dividend Per Share	-	-	-	-
Total Operating Income As Reported	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-
Rent Expense Supplemental	-	-	-	-
Total Expenses	$ 3.74M	$ -65.06M	$ 4.57M	$ 105.75K
Net Income From Continuing And Discontinued Operation	$ -56.82M	$ -49.97M	$ -4.54M	$ -90.84K
Normalized Income	$ -18.91M	-	-	$ -90.84K
Interest Expense	-	-	-	-
EBIT	$ -65.76M	$ -64.47M	$ -4.57M	$ -105.75K
EBITDA	$ -53.41M	$ -64.46M	$ -4.57M	$ -105.75K

Currency in USD

MoonLake Immunotherapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing